ArticlePloS one2013
Anti-müllerian hormone is not associated with cardiometabolic risk factors in adolescent females.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Trial
- Anti-Müllerian Hormone Levels Are Associated With Skeletal Maturity in Adolescent Girls: A Longitudinal Study.Health science reports · 2025Article
- Dietary acid load and risk of diminished ovarian reserve: a case-control study.Reproductive biology and endocrinology : RB&E · 2024Article
- High physical activity and ovarian reserve: a prospective study of normo-ovulatory professional athletes.Journal of ovarian research · 2022Observational
- Anti-Müllerian hormone levels and risk of type 2 diabetes in women.Diabetologia · 2021Article
- Association of the functional ovarian reserve with serum metabolomic profiling by nuclear magnetic resonance spectroscopy: a cross-sectional study of ~ 400 women.BMC medicine · 2020Article
- Association between ovarian reserve and preeclampsia: a cohort study.BMC pregnancy and childbirth · 2019Article
- Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.Fertility and sterility · 2017Article
- Maternal Pre-pregnancy BMI and Reproductive Health of Daughters in Young Adulthood.Maternal and child health journal · 2016Article
- Genome-wide association study identifies common and low-frequency variants at the AMH gene locus that strongly predict serum AMH levels in males.Human molecular genetics · 2016Article
- Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome.Nature communications · 2015Article
- Assessing pubertal status in multi-ethnic primary schoolchildren.Acta paediatrica (Oslo, Norway : 1992) · 2015Article
- Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study.Human reproduction (Oxford, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesEpidemiological evidence for associations of Anti-Müllerian hormone (AMH) with cardiometabolic risk factors is lacking. Existing evidence comes from small studies in select adult populations, and findings are conflicting. We aimed to assess whether AMH is associated with cardiometabolic risk factors in a general population of adolescent females.
methodsAMH, fasting insulin, glucose, HDLc, LDLc, triglycerides and C-reactive protein (CRP) were measured at a mean age 15.5 years in 1,308 female participants in the Avon Longitudinal Study of Parents and Children (ALSPAC). Multivariable linear regression was used to examine associations of AMH with these cardiometabolic outcomes.
resultsAMH values ranged from 0.16-35.84 ng/ml and median AMH was 3.57 ng/ml (IQR: 2.41, 5.49). For females classified as post-pubertal (n = 848) at the time of assessment median (IQR) AMH was 3.81 ng/ml (2.55, 5.82) compared with 3.25 ng/ml (2.23, 5.05) in those classed as early pubertal (n = 460, P≤0.001). After adjusting for birth weight, gestational age, pubertal stage, age, ethnicity, socioeconomic position, adiposity and use of hormonal contraceptives, there were no associations with any of the cardiometabolic outcomes. For example fasting insulin changed by 0% per doubling of AMH (95%CI: -3%,+2%) p = 0.70, with identical results if HOMA-IR was used. Results were similar after additional adjustment for smoking, physical activity and age at menarche, after exclusion of 3% of females with the highest AMH values, after excluding those that had not started menarche and after excluding those using hormonal contraceptives.
conclusionOur results suggest that in healthy adolescent females, AMH is not associated with cardiometabolic risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.